Shots:
- VERAXA to reverse merge with Voyager, where the combined entity- “VERAXA Biotech” will be listed on Nasdaq under VERX ticker; closing expected in Q4’25
- As per the deal, VERAXA will have access to ~$253M cash from Voyager’s trust at closing & contribute ~$1.3B in equity for ~130M shares, with all shareholders rolling over 100% equity, valuing the combined entity at ~$1.64B (at $10/share). VERAXA is also raising a crossover round to fund operations for 2yrs., excl. partnerships, which is expected to close before merger
- VERAXA’s pipeline contains 9 programs incl. VX-A901 in P-I for leukemia & aims to advance 3 clinical programs & expand licensed assets by 2029
Ref: Globenewswire | Image: VERAXA & Voyager
Related News:- Alumis and ACELYRIN Revise Merger Agreement, Boosting ACELYRIN Stake
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
